Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Rating Upgraded by Wall Street Zen

Recursion Pharmaceuticals (NASDAQ:RXRX) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Several other analysts also recently commented on RXRX. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.06.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $3.34 on Friday. The stock’s 50 day moving average price is $3.32 and its 200 day moving average price is $3.34. The company has a market capitalization of $1.79 billion, a PE ratio of -3.21 and a beta of 1.03. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same quarter in the prior year, the firm posted ($0.41) EPS. On average, research analysts anticipate that Recursion Pharmaceuticals will post -0.92 EPS for the current year.

Insider Activity at Recursion Pharmaceuticals

In other news, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the transaction, the chief executive officer directly owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $3.25, for a total value of $97,500.00. Following the sale, the director directly owned 6,188,287 shares in the company, valued at approximately $20,111,932.75. The trade was a 0.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 131,937 shares of company stock worth $478,874 over the last quarter. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of RXRX. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 18.6% during the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after buying an additional 7,407,606 shares in the last quarter. ARK Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock valued at $152,626,000 after buying an additional 3,771,357 shares during the period. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 38.7% during the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after buying an additional 7,064,963 shares during the period. Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company’s stock worth $44,731,000 after acquiring an additional 1,310,695 shares during the last quarter. Finally, Norges Bank acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth approximately $23,473,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.